N.N. Alexandrov National Cancer Centre
5 clinical trials · Sponsor
◉ Watch N.N. Alexandrov National Cancer Centre
| Record | Firm | Date |
|---|---|---|
| Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus (NCT07720310) | N.N. Alexandrov National Cancer Centre | 2026-03-09 |
| PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer (NCT07472153) | N.N. Alexandrov National Cancer Centre | 2025-07-01 |
| PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer (NCT07472140) | N.N. Alexandrov National Cancer Centre | 2025-07-01 |
| Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma (NCT07524816) | N.N. Alexandrov National Cancer Centre | 2021-06-01 |
Track N.N. Alexandrov National Cancer Centre automatically
Every clearance here is in the API, with alerts when new ones post.